Low Dose Naltrexone

By using LDN, we are modulating the OGF-OGFr axis which helps balances the immune system and works towards slowing down disease progression. Research is showing that for some diseases there aren’t enough OGF receptors for the OGF to attach on to. Other diseases have too many receptors and not enough opioids. Either creates an imbalance which needs correcting. Please see this link for further information which we will be updating as more studies are published furthering our understanding about using this novel therapy.

Understanding the OGF-OGFr axis as a homeostatic regulator of proliferation has substantial implications for maintaining human health and treatment of disease. More..

MULTIPLE SCLEROSIS

Astrocyte Proliferation is Regulated by the OGF-OGFr Axis In Vitro and in Experimental Autoimmune Encephalomyelitis (2013)

OGF arrests the progression of clinical disease and spinal cord pathology in established EAE (2012)

Prevention and diminished expression of EAE by LDN or OGF: Therapeutic implications for multiple sclerosis (2011)

T lymphocyte proliferation is suppressed by the OGF-OGFr axis: Implication for the treatment of autoimmune diseases (2011)

B lymphocyte proliferation is suppressed by the OGF-OGFr axis: Implication for the treatment of autoimmune diseases (2011)

CANCER

The OGF-OGFr axis is a physiological determinant of cell proliferation in diverse human cancers (2009)

ANGIOGENSIS

Opioid growth factor modulates angiogenesis (2012)

BREAST CANCER

Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers (2014)